Form 4: Phibro Animal Health CEO Sells Shares Under 10b5-1 Plan

Phibro Animal Health's President and CEO, Jack Bendheim, along with BFI Co., LLC, sold 7,040 shares of Class A Common Stock in late November and early December 2025.

Summary

• Jack Bendheim, President and CEO, Director, and 10% Owner of Phibro Animal Health Corp (PAHC), along with BFI Co., LLC, a 10% owner, reported sales of Class A Common Stock.
• On November 28, 2025, 3,520 shares were sold at a weighted average price of $42.5398 per share, with prices ranging from $42.12 to $43.02.
• On December 1, 2025, an additional 3,520 shares were sold at a weighted average price of $41.658 per share, with prices ranging from $41.38 to $41.895.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted by BFI Co., LLC on May 30, 2025.
• Following these transactions, BFI Co., LLC indirectly holds 26,800 shares, and Jack Bendheim directly holds 16,840 shares.
• Jack Bendheim exercises voting and dispositive power over BFI Co., LLC and disclaims beneficial ownership of those securities except to the extent of his pecuniary interest.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to insider selling by a key executive and 10% owner. However, the negative impact is mitigated by the fact that the sales were pre-planned under a Rule 10b5-1 trading plan, suggesting the transactions were not based on new, adverse information.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which indicates the transactions were not based on new, non-public information and can reduce the perception of opportunistic selling.
• The shares were sold at relatively strong prices, ranging from $41.38 to $43.02, indicating a favorable market for the sales.

Negatives

• The President and CEO, a key insider and 10% owner, reduced his beneficial ownership in the company, which can sometimes be interpreted negatively by investors.
• A total of 7,040 shares were sold, representing a reduction in the insider's stake.

Risks

• Insider selling, even under a 10b5-1 plan, can sometimes lead to negative market sentiment or speculation about the company's future prospects.
• A reduction in insider ownership might be perceived as a lack of confidence, potentially impacting investor perception and share price.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This insider transaction report is specific to Phibro Animal Health Corp and does not directly provide broader industry trends or competitive analysis. However, insider trading activity is a common data point monitored by analysts across all industries to gauge management's confidence.

Related Party Transactions

• The transactions involve Jack Bendheim, who is the President and CEO, a Director, and a 10% Owner of Phibro Animal Health Corp.
• BFI Co., LLC, which directly holds some of the reported securities, is also a 10% owner, and Jack Bendheim exercises voting and dispositive power over BFI Co., LLC.

Stakeholder Impact

• Shareholders may interpret the insider sales as a signal, potentially leading to questions about management's long-term confidence in the company, although the 10b5-1 plan mitigates this concern.
• The reduction in beneficial ownership by a key executive could influence investor sentiment.

Key Dates

Recommendation

While insider selling by a CEO and 10% owner can be a yellow flag, the fact that these sales were executed under a pre-arranged Rule 10b5-1 plan reduces the immediate concern of opportunistic selling based on negative undisclosed information. Without additional company-specific financial or operational updates, a 'hold' recommendation is appropriate, advising investors to monitor future company performance and insider activity rather than making a strong buy or sell decision solely based on this Form 4.

Keywords

Phibro Animal Health Corp, PAHC, Jack Bendheim, Insider Sale, Form 4, 10b5-1 Plan, Stock Transaction, CEO, Director, 10% Owner